Int. J. Mol. Sci. 2013, 14(7), 14800-14832; doi:10.3390/ijms140714800
Review

Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer

Received: 8 May 2013; in revised form: 27 June 2013 / Accepted: 27 June 2013 / Published: 16 July 2013
(This article belongs to the Special Issue Molecular Research in Urology)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: As our understanding of the molecular pathways driving tumorigenesis improves and more druggable targets are identified, we have witnessed a concomitant increase in the development and production of novel molecularly targeted agents. Radiotherapy is commonly used in the treatment of various malignancies with a prominent role in the care of prostate cancer patients, and efforts to improve the therapeutic ratio of radiation by technologic and pharmacologic means have led to important advances in cancer care. One promising approach is to combine molecularly targeted systemic agents with radiotherapy to improve tumor response rates and likelihood of durable control. This review first explores the limitations of preclinical studies as well as barriers to successful implementation of clinical trials with radiosensitizers. Special considerations related to and recommendations for the design of preclinical studies and clinical trials involving molecularly targeted agents combined with radiotherapy are provided. We then apply these concepts by reviewing a representative set of targeted therapies that show promise as radiosensitizers in the treatment of prostate cancer.
Keywords: prostate cancer; radiotherapy; radiosensitizer; molecularly targeted agents; HSP90 inhibitors
PDF Full-text Download PDF Full-Text [289 KB, uploaded 19 June 2014 05:01 CEST]

Export to BibTeX |
EndNote


MDPI and ACS Style

Alcorn, S.; Walker, A.J.; Gandhi, N.; Narang, A.; Wild, A.T.; Hales, R.K.; Herman, J.M.; Song, D.Y.; DeWeese, T.L.; Antonarakis, E.S.; Tran, P.T. Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer. Int. J. Mol. Sci. 2013, 14, 14800-14832.

AMA Style

Alcorn S, Walker AJ, Gandhi N, Narang A, Wild AT, Hales RK, Herman JM, Song DY, DeWeese TL, Antonarakis ES, Tran PT. Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer. International Journal of Molecular Sciences. 2013; 14(7):14800-14832.

Chicago/Turabian Style

Alcorn, Sara; Walker, Amanda J.; Gandhi, Nishant; Narang, Amol; Wild, Aaron T.; Hales, Russell K.; Herman, Joseph M.; Song, Danny Y.; DeWeese, Theodore L.; Antonarakis, Emmanuel S.; Tran, Phuoc T. 2013. "Molecularly Targeted Agents as Radiosensitizers in Cancer Therapy—Focus on Prostate Cancer." Int. J. Mol. Sci. 14, no. 7: 14800-14832.

Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert